Innate immunity and regulatory T-cells in human Chagas disease: what must be understood?
AUTOR(ES)
Sathler-Avelar, Renato, Vitelli-Avelar, Danielle Marquete, Teixeira-Carvalho, Andréa, Martins-Filho, Olindo Assis
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2009-07
RESUMO
There is a general consensus that during chronic Trypanosoma cruzi infection, the host immune system induces complex processes to ensure the control of parasite growth while preserving the potential to mount and maintain a life-long controlled humoral and cellular immune response against the invading pathogen. This review summarises evidence in an attempt to elucidate "what must be understood" to further clarify the role of innate immunity in the development/maintenance of clinical Chagas disease and the impact of etiological treatment on host immunity, highlighting the contributions of the innate immunity and regulatory T (Treg) cells. Recently, increasing focus on innate immunity suggest that chronic T. cruzi infection may cause morbidity when innate effector functions, or the down-regulation of adaptive regulatory mechanisms are lacking. In this context, stable asymptomatic host-parasite interactions seem to be influenced by the effector/regulatory balance with the participation of macrophages, natural killer (NK) and CD8+ T cells in parallel with the establishment of regulatory mechanisms mediated by NKT and Treg cells. Moreover, a balanced innate immune activation state, apart from Treg cells, may play a role in controlling the adverse events triggered by the massive antigen release induced by trypanosomicidal agents during Chagas disease etiological treatment.
Documentos Relacionados
- HIV Infection of Naturally Occurring and Genetically Reprogrammed Human Regulatory T-cells
- Suppressor T-cells in BCG-infected mice.
- Docosahexaenoic acid reduces suppressive and migratory functions of CD4CD25 regulatory T-cells
- Development of Suppressor T-Cells in Mycobacterium habana-Infected Mice
- Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma